Sotirova, Tatjana

Preferred name

Sotirova, Tatjana

Official Name

Sotirova, Tatjana

Main Affiliation

Now showing 1 - 10 of 47

Some of the metrics are blocked by your
consent settings
CML-053 Health-Related Quality of Life in Macedonian Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: EQ-5D-5L Assessment
(Elsevier BV, 2024-09)
;
;
Popova Labachevska, Marija
;
Stojanovska Jakimovska, Simona
;
Trpkovska Terzieva, Slobodanka
Some of the metrics are blocked by your
consent settings
The evaluation of some markers of proximal renal tubules damage in patient with psoriatic arthritis
(Macedonian Medical Association, 2018)
;
;
;
;
Some of the metrics are blocked by your
consent settings
Case report of a rare coagulation disorder-Acquired hemophilia A
(Medical Faculty, Ss. Cyril and Methodius University in Skopje, 2016)
;
;
Ivanovski Martin
;
;
Some of the metrics are blocked by your
consent settings
Chronic lymphocytic leukemia following successfull treatment of Hodgkin’s lymphoma: report of two patients
(Македонско лекарско друштво = Macedonian Medical Association, 2017)
;
;
;
;
Arif Latifi
Over the past few decades, introducing effective therapy, improved staging procedures, and significant improvement of supportive measures, significantly improved the prospects for patients with Hodgkin's lymphoma, leading to a 75-90% cure rate. Hodgkin's lymphoma survivors are at high risk of developing a large variety of second malignant neoplasms. It is crucial to maintain awareness regarding this issue. The subsequent development of Chronic Lymphocytic Leukemia (CLL) in patients after successful treatment of Hodgkin's lymphoma (HL) is an extremely rare possibility. The relationship between these two lymphoproliferative disorders is unclear. Herein we describe two cases of CLL, developed in previously treated patients with HL, with characterization of two distinct lymphoproliferative disease in these two patients. We also systematically reviewed the existing literature on this very rare occurrence of treatment-induced second hematological malignancies.
Some of the metrics are blocked by your
consent settings
Long-Term Efficacy of Treatment in Elderly Patients With Hodgkin Lymphoma: A Retrospective Analysis
(Elsevier BV, 2024-09)
Terzieva, Slobodanka Trpkovska
;
;
;
;
Some of the metrics are blocked by your
consent settings
Health-Related Quality of Life in Macedonian Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: EQ-5D-5L Assessment
(Elsevier BV, 2024-09)
;
;
Popova Labachevska, Marija
;
Stojanovska Jakimovska, Simona
;
Trpkovska Terzieva, Slobodanka
Some of the metrics are blocked by your
consent settings
HL-210 Long-Term Efficacy of Treatment in Elderly Patients With Hodgkin Lymphoma: A Retrospective Analysis
(Elsevier BV, 2024-09)
Trpkovska Terzieva, Slobodanka
;
;
;
;
Genadieva Stavrik, Sonja
Some of the metrics are blocked by your
consent settings
Early Ultrasound Screening for Fetal Malformations in the Second Pregnancy after Combined Modality Treatment for Hodgkin’s Disease: A Case Report
(SCVISION Publishers, 2017-11)
;
Jordancho Ivanov
;
ABSTRACT Introduction: Therapeutic progress in HD has led to a high rate of cure, but at the expense of some side effects. Abnormalities reported so far are: cardiac toxicity, pulmonary toxicity, endocrinal failure, second cancers and congenital malformations. Although several studies reported in the literature showed no or slightly increased risk of congenital abnormalities among newborns of women previously treated for Hodgkin’s disease compared with the general population, abnormalities do occur and sometimes they are very odd and difficult. This is the first report of delayed appearance of specific malformations found in the literature. Case Report: We report a case of female patient, 25 years old, macedonian, presented with Hodgkin’s disease, subtype nodular sclerosis, stage IIIA. The patient received chemotherapy according to ABVD protocol – 6 cycles. Thereafter she received mantle field radiation with 3600 cGy. The first and normal pregnancy occurred after 36 months. Second pregnancy occurred 87 months after completion of treatment. At 13th gestational week ultrasound assessment revealed malformations and induced abortion was performed. A male fetus with malformations on the head such as proboscis, cyclopia and omphalocele on the front abdominal wall containing liver and small bowels was found. Conclusion: I consider this case important in bringing the potential late side-effect to the attention of both patients and doctors. They should be alert for the risk of congenital abnormalities in newborns of women previously treated for Hodgkin’s disease, especially with combined modality treatment, and should check for them during pregnancy, at birth, in early childhood, or in adulthood. Thus, odd and difficult malformations could be avoided.
Some of the metrics are blocked by your
consent settings
Immune thrombocytopenic purpura in adults in the last 10 years: single-centre experience
(Македонска академија на науките и уметностите, Одделение за биолошки и медицински науки = Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences, 2012)
;
Trpkovska-Terzieva S
;
;
Latifi A
;
Abstract Background: Immune thrombocytopenic purpura (ITP) is a benign disease with low morbidity and mortality and frequent remissions that occur spontaneously or in response to first-line treatment with steroids or splenectomy. Aim: The purpose of this study is to describe the clinical outcomes of 170 patients with ITP diagnosed and/or treated in our hospital between 2000 and 2010. Methods and results: The median age at diagnosis was 47 years. Forty three (25%) were asymptomatic, 65% had minor skin or mucosal bleeding and 10% had significant bleeding from the gastrointestinal or genitourinary system. The median platelet count at diagnosis was 13x10(9)/L (range: 0-98x10(9)/L). Median follow-up of all patients was 13 months. Ninety-five patients had a follow-up longer than 12 months, with median 44 months (range 14-384). Corticosteroids were the initial treatment for 161/170 (95%) patients, 38 (22%) were splenectomized, 25 (14.7%) were treated with intravenous gamma globulins, while 9 did not received any specific treatment. A complete response to initial treatment (prednisone±splenectomy) was achieved in 55/161 (34.2%), a partial response in 90 (55.9%) and no response in 16 (9.9%) patients. In the group of patients with follow-up longer than 1 year; 28 (29%) patients had refractory or unresponsive ITP with a median follow-up of 66 months. All patients with refractory ITP were treated with steroids, 11 were splenctomized, significantly more patients with refractory ITP 12 (43%) were treated with IVIG compared with other ITP patients (16%), p=0.005. The median age of 38 splenectomized patients was 28 years and it is significantly different from the other patients (p<0.001). There were no significant differences in other characteristics between splenctomized or refractory ITP and other patients at diagnosis. Conclusion: Our results were similar to results already reported in other similar studies.
Some of the metrics are blocked by your
consent settings
Overall survival in myelodysplastic syndromes: a cohort study
(Quest Journals, 2014-12-25)
;
;
;
Svetlana Krstevska
;
Factors like age, gender, FAB subtypes, cytopenias, proportion of bone marrow (BM) blasts, comorbidities, transfusion dependence, albumins, lactate dehydrogenase (LDH), karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS. The aim of this study was to evaluate factors that influence overall survival (OS) in MDS. We conducted retrospective cohort study of 184patients (98 male, 86 female) with MDS who presented to the University Clinic of Hematology, Skopje, Macedonia, from January 2011 to October 2014. The differences in OS between male and female were not significant (p = .08368). The mean age at diagnosis was 66,5 years. Differences in OS among FAB subtypes were significant (p = .00117). OS inversely correlated with BM blast percentage (p = .00054). Hemoglobin, platelets and absolute neutrophil count (ANC) did not influence OS - p=0.107161, (p= .79288) and (p= .94860), respectfully. Ferritin (p = .63575), LDH and transfusion (p= .48247) did not influence OS. Albumins and comorbidities influenced OS (p= .01137 and p= .00184, respectfully). We can conclude that FAB subtypes, BM blast percentage, albumins and comorbidities had an influence on OS, while age, gender, hemoglobin, platelet count, ANC, transfusion dependence and LDH had no impact on OS.

Sotirova, Tatjana

Filters

Settings

Sort By

Results per page